全文获取类型
收费全文 | 295篇 |
免费 | 18篇 |
国内免费 | 3篇 |
专业分类
儿科学 | 29篇 |
妇产科学 | 2篇 |
基础医学 | 42篇 |
口腔科学 | 2篇 |
临床医学 | 49篇 |
内科学 | 55篇 |
皮肤病学 | 16篇 |
神经病学 | 10篇 |
特种医学 | 31篇 |
外科学 | 14篇 |
综合类 | 10篇 |
预防医学 | 21篇 |
眼科学 | 6篇 |
药学 | 20篇 |
1篇 | |
肿瘤学 | 8篇 |
出版年
2021年 | 5篇 |
2020年 | 4篇 |
2018年 | 6篇 |
2016年 | 6篇 |
2015年 | 10篇 |
2014年 | 6篇 |
2013年 | 5篇 |
2012年 | 10篇 |
2011年 | 8篇 |
2010年 | 10篇 |
2009年 | 14篇 |
2008年 | 3篇 |
2007年 | 5篇 |
2006年 | 6篇 |
2005年 | 7篇 |
2004年 | 9篇 |
2003年 | 3篇 |
2002年 | 3篇 |
2001年 | 4篇 |
2000年 | 6篇 |
1999年 | 5篇 |
1998年 | 8篇 |
1997年 | 21篇 |
1996年 | 8篇 |
1995年 | 8篇 |
1994年 | 10篇 |
1993年 | 7篇 |
1992年 | 5篇 |
1991年 | 5篇 |
1990年 | 3篇 |
1989年 | 10篇 |
1988年 | 12篇 |
1987年 | 5篇 |
1986年 | 4篇 |
1985年 | 5篇 |
1984年 | 5篇 |
1983年 | 3篇 |
1982年 | 5篇 |
1981年 | 7篇 |
1980年 | 4篇 |
1978年 | 3篇 |
1977年 | 11篇 |
1976年 | 6篇 |
1975年 | 3篇 |
1974年 | 4篇 |
1973年 | 3篇 |
1972年 | 6篇 |
1964年 | 2篇 |
1963年 | 1篇 |
1943年 | 1篇 |
排序方式: 共有316条查询结果,搜索用时 15 毫秒
21.
J Termote NE Schalij-Delfos BP Cats D Wittebol-Post BR Hoogervorst HAA Brouwers 《Acta paediatrica (Oslo, Norway : 1992)》1996,85(12):1491-1496
To assess the effect of surfactant replacement therapy (SRT) on the prevalence and severity of retinopathy of prematurity (ROP), we compared data from 160 SRT-treated preterm infants with data from 230 historic controls. The prevalence of ROP was 30.6% in the treatment group and 23.4% in the control group. Severe ROP (stages 3-4) was seen in 6.1% of the infants with ROP in the treatment group and 20.3% of the ROP patients in the control group. Surfactant therapy had no influence on the prevalence of ROP (odds ratio 1.4, 95% confidence interval 0.797-2.459, p = 0.242). However, SRT was associated with a decreased risk for severe ROP, compared to mild ROP (odds ratio 0.226, 95% confidence interval 0.056-0.905, p = 0.036). These data suggest that SRT is associated with a decreased risk for severe ROP. 相似文献
22.
Plesner T; Ploug M; Ellis V; Ronne E; Hoyer-Hansen G; Wittrup M; Pedersen TL; Tscherning T; Dano K; Hansen NE 《Blood》1994,83(3):808-815
The cellular receptor for urokinase-type plasminogen activator (uPAR) binds pro-urokinase (pro-uPA) and facilitates its conversion to enzymatically active urokinase (uPA). uPA in turn activates surface- bound plasminogen to plasmin, a process of presumed importance for a number of biologic processes including cell migration and resolution of thrombi. We have previously shown that uPAR is expressed on the plasma membrane of circulating neutrophils, and we now report that stimulation with phorbol myristate acetate (PMA), FMLP, or tumor necrosis factor- alpha results in a rapid increase in the expression of uPAR. This process is accompanied by an increased cell-associated plasminogen activation after preincubation of neutrophils with pro-uPA in vitro. By subcellular fractionation of unstimulated neutrophils, 50% of uPAR is recovered in fractions containing latent alkaline phosphatase, corresponding to an intracellular compartment of easily mobilizable secretory vesicles distinct from both primary and specific granules, whereas the remaining 50% of uPAR is associated with a compartment eluting close to the specific granules. In contrast, the ligand pro-uPA is primarily (approximately 80%) found in the specific granules, but small amounts of pro-uPA/uPA (approximately 20%) coelute with latent alkaline phosphatase. Stimulation of neutrophils with FMLP results in translocation of uPAR as well as of pro-uPA from the secretory vesicles, whereas stimulation with PMA is required to translocate material from specific granules. Flow cytometry of neutrophils saturated with exogenous diisopropyl fluorophosphate-uPA shows a large excess (approximately 90%) of unoccupied uPAR on resting as well as FMLP- and PMA-stimulated neutrophils, suggesting a possible role for exogenous pro-uPA in providing neutrophils with a potential for plasminogen activation. These processes may be important for neutrophil extravasation and migration through extracellular matrix and for the contribution of neutrophils to resolution of thrombi. 相似文献
23.
HÉLÉNE ELTCHANINOFF M.D. CARLOS GIRON M.D. RAPHAËLLE CARLOT M.D. CATHERINE BIZET M.D. STEPHAN CHASSAING M.D. ALAIN CRIBIER M.D. 《Journal of interventional cardiology》2000,13(4):295-299
Introduced more than 15 years ago, balloon aortic valvuloplasty (BAV) has clearly delineated indications and limitations. Although, aortic valve replacement is undoubtedly the treatment of choice for healthy patients with aortic stenosis, BAV has been demonstrated as a valuable and safe palliative procedure for patients considered too risky or old for current day surgery. Between January 1991 and December 1999, 858 patients (mean age 76 ± 11 years, 479 [57%] women) underwent BAV at our center. Indications for BAV were contraindication to surgery in 16.2% of the patients, high risk in 40.4%, refusal of surgery in 10.7%, personal decision in 18.5%, and other in 14.2%. The mean gradient decreased from 65 ± 23 to 27 ± 12 mmHg and the valve area increased from 0.56 ± 0.19 cm2 to 1.0 ± 0.38 cm2 . Eleven (1.1%) patients died during the procedure. The other severe complications were complete AV block in 18 (1.8%) patients, stroke in 8 (0.8%), tamponade in 6 (0.6%), and massive aortic insufficiency in 4 (0.4%). In conclusion, BAV does not replace valve replacement, even in the elderly. All those who can be operated on, should be. However, if surgical intervention is not considered reasonable, BAV offers good immediate results with an acceptable complication rate. Furthermore, previous published series have demonstrated that BAV is particularly indicated in specific subgroups, such as very old patients with high operative risk, end-stage heart failure, cardiogenic shock, or general anesthesia for noncardiac surgery. 相似文献
24.
003 胺碘酮可作为心房纤颤转复为窦性心律的首选药物 总被引:1,自引:0,他引:1
在美国,胺碘酮仅被批准用于治疗致命性室性心律失常,而在其他国家,尤其是南欧,也被广泛用于心房纤颤(Af)的治疗。然而有关胺碘酮复律效果报道不一,其成功率在16%~92%。本文前瞻性随机对照研究胺碘酮作为Af复律的首选药物的疗效及安全性。 连续208例症状性Af,男性102例,女性106例,年龄27~78(65±10)岁。将受试者随机分为胺碘酮治疗组与安慰剂组。胺碘酮用法:300mg静脉注射,持续1小时,然后以20mg/kg静脉滴注,持续24小时,继之口服200mg,tid,共1周,400mg/d共3周。如果受试者此前未用地高辛,则给予地高辛0.5mg静脉注射,2小时后再静脉注射0.25mg,继之静脉注射0.25mg,q6h,共24小时,此后调整地高辛剂量以维持治疗剂量的血清浓度,对Af持续48小时以上或持续时间不明、未用抗凝药物者均应用醋硝香豆素(acenocoumaro1),至少21天,复律成功者继续用药21天,未成功者用药时间不定。本研究将Af持续1个月以上者定义为慢性Af,<24小时者定义为新近发作Af,其余定义为持续性Af。 相似文献
25.
26.
A retrospective study on chemical and radioactive synovectomy in severe haemophilia patients with recurrent haemarthrosis 总被引:7,自引:0,他引:7
P. MOLHO P. VERRIER N. STIELTJES J.-M. SCHACHER N. OUNNOUGHÈNE D. VASSILIEFF C.-J. MENKES & Y. SULTAN 《Haemophilia》1999,5(2):115-123
Between 1970 and 1994, 116 chemical and 90 radioactive synovectomies were performed in 107 patients with severe haemophilia and two with type 3 von Willebrand's disease. The products used were osmic acid (OA) in 100 cases, 90-Yttrium in 35 cases, 186-Rhenium in 48, 169-Erbium in two, hexacetonide triamcinolone in 16 and radioactive gold in five cases. The use of radioactive colloids is not allowed in France in patients under 15 years of age. Twenty-nine patients had more than one synovectomy per joint. All patients were evaluated for 6 months post-synovectomy, using both a clinical and a radiological score. Six months after synovectomy, a good or excellent result was obtained for 81% of the joints treated with isotopes, compared with 44% of those treated with OA, P<0.001. This superiority of isotopes over osmic acid was still observed after 6 months for the 89 joints that were re-evaluated, with follow-up ranging from 1 to 9 years. It was possible to calculate a radiological score in 84 cases. With OA the best results were from the joints with the lowest scores pre-synovectomy (<7). No correlation could be established between the clinical and the radiological scores, due to the small size of the sample. In summary: (1) chemical and radioactive synovectomy are simple and safe procedures for haemophilic arthropathy, (2) in our series, after 6 months the efficacy of isotopic synovectomy was greater than that of chemical synovectomy, and this benefit seems to persist after 6 months, and up to 9 years in the group of patients with longer-term follow-up. 相似文献
27.
Vadhan-Raj S; Broxmeyer HE; Andreeff M; Bandres JC; Buescher ES; Benjamin RS; Papadopoulos NE; Burgess A; Patel S; Plager C 《Blood》1995,86(6):2098-2105
PIXY321 is a novel fusion protein of recombinant human granulocyte- macrophage colony-stimulating factor and interleukin-3 that exhibits biologic effects of both its parent cytokines in vitro and in preclinical studies. To evaluate the clinical safety and hematopoietic effects of this hybrid cytokine, PIXY321 was administered by subcutaneous injection twice daily at doses of 25 to 1,000 micrograms/m2/day over 14 days to 24 patients with sarcoma before chemotherapy as part of a phase I trial. The treatment was associated with significant increases in white blood cell, neutrophil, platelet, and reticulocyte counts (all P < .001). The increase in neutrophil count was dose-related and was seen during treatment with the cytokine, whereas the increase in platelet count was gradual and peaked after the cessation of the cytokine treatment and was not clearly dose related. PIXY321 treatment also increased bone marrow (BM) cellularity and the percentage of BM cells in S phase (P < .001). In addition, there was a significant increase in the number of CD34+ cells and committed and multipotential progenitors in the peripheral blood. The ex vivo expansion capacity of peripheral blood and BM progenitor cells was preserved after the in vivo treatment with PIXY321. The treatment was well tolerated, with the most common side-effect being injection site reactions. The results of this study show the biologic and clinical activity of a genetically engineered fusion molecule of two hematopoietic cytokines in humans with normal hematopoietic function. 相似文献
28.
Human platelets exert cytotoxic effects on tumor cells 总被引:6,自引:0,他引:6
Monocytes are thought to play a role in host resistance to tumor cell growth in animals and humans. In addition, platelets are known to be involved in tumor metastases. To investigate the interaction of these two cell types and their effect on tumor cells, human monocytes and platelets were examined using an in vitro monocyte-tumor cell cytotoxicity assay. Monocytes alone resulted in 32% +/- 1.5 (mean +/- SEM) tumor cell kill. When platelets were added to monocytes in a 1:1 ratio, an increase in cytotoxicity to 61% +/- 3.2 was observed. The cytotoxicity noted when platelets were added to a fixed number of monocytes and tumor cells was dependent on the number of platelets added. A decrease in cytotoxicity from 32% +/- 1.5 to 12% +/- 2.3 was observed when contaminating platelets were removed from monocyte preparations. Platelets added to tumor cells in the absence of any monocytes were also toxic, resulting in a maximum kill of 95% at a 4:1 platelet/tumor cell ratio. Secreted products of freshly isolated platelets may be responsible for much of the observed cytotoxicity, since supernatants from the platelets were toxic for tumor cells. Platelets pretreated with a cyclooxygenase inhibitor (ASA) or a lipoxygenase inhibitor had decreased cytotoxicity compared with untreated platelets. Our results indicate that products of platelet arachidonate metabolism are toxic for tumor cell lines. They also suggest that the role of the platelet must be considered when studying monocyte-tumor cell cytotoxicity. 相似文献
29.
Catovesky D; Costello C; Loukopoulos D; Fessas PR; Foxley JM; Traub NE; Mills MJ; O'Brien M 《Blood》1981,57(4):758-763
We describe three patients who had typical features of hairy cell leukemia (HCL) and multiple myeloma (MM) at the same time. In two, both diagnoses were made within a short period of time, and in the third, HCL had been present for 2 yr before the appearance of a paraprotein, bone lesions, and plasma-cell infiltrates established the diagnosis of MM. Although this association has not been previously reported, cases of HCL with osteolytic lesions or a paraprotein band have been described. The cases described may represent clinical manifestations of closely related disorders arising from divergent differentiation from a common B-cell precursor rather than a chance association. 相似文献
30.
Alternating poly(Glu-Leu) was synthesized by the condensation of the corresponding dipeptide p-nitrophenyl ester at high concentration. It exhibits a random coil structure in pure water at neutral pH. Addition of monovalent cations, such as NH+4 to a final 0.1 M solution, induces a transition to a water soluble β-structure. The salt effect is quite selective since no transition was observed with Li+, Na+ or Cs+ ions. Addition of 0.5 equiv. of calcium, cobalt or manganese chlorides per glutamyl residue induces similar coil to β-sheet transitions. No polymer precipitation was observed at these very low salt concentrations. Addition of 0.5 equiv. of Cu2+ or 0.15 equiv. of Fe3+ induces a coil to α-helix transition. Molecular modeling has been used to understand tentatively the main factors controlling the different conformations observed with the various metal ions. © Munksgaard 1997. 相似文献